| S1061 |
Nutlin-3
|
Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with an IC50 of 90 nM in a cell-free assay; it stabilises p73 in p53-deficient cells.
|
-
Cancer Discov, 2025, 15(1):69-82
-
iScience, 2025, 28(6):112635
-
Biomed Rep, 2025, 22(4):65
|
|
| S7030 |
RG-7112
|
RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor with HTRF IC50 of 18 nM.
|
-
NPJ Aging, 2025, 11(1):6
-
Int J Mol Sci, 2024, 25(7)3948
-
bioRxiv, 2024, 2024.10.09.617493
|
|
| S8059 |
Nutlin-3a
|
Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
|
-
Nucleic Acids Res, 2025, 53(13)gkaf627
-
Cell Rep Med, 2025, 6(8):102284
-
Bone Res, 2025, 13(1):62
|
|
| E1491 |
Brigimadlin
|
Brigimadlin (BI 907828) is a potent, orally active inhibitor of E3 ubiquitin-protein ligase MDM-2. This compound inhibits MDM-2's suppression of the tumour suppressor p53. It promotes Apoptosis and enhances the transcription of p53 targets such as p21 and PUMA in BT48, BT67, and BT73 cells.
|
|
|
| S3604 |
Triptolide
|
Triptolide is a diterpene triepoxide, an immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii. It functions as a NF-κB inhibitor with dual actions by disruption of p65/CBP interaction and by reduction of p65 protein. Triptolide (PG490) abrogates the transactivation function of heat shock transcription factor 1 (HSF1). Triptolide inhibits MDM2 and induces apoptosis through a p53-independent pathway.
|
-
Mol Cell, 2025, S1097-2765(25)00316-8
-
Mol Cell, 2025, 85(15):2839-2853.e8
-
Chin Med, 2025, 20(1):122
|
|
| S7205 |
Idasanutlin (RG7388)
|
Idasanutlin (RG7388) is a potent and selective p53-MDM2 inhibitor with an IC50 of 6 nM, and it shows improved in vitro binding as well as cellular potency/selectivity.
|
-
Nat Commun, 2025, 16(1):2229
-
Leukemia, 2025, 39(12):2881-2894
-
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136
|
|
| S7649 |
SAR405838
|
SAR405838 is an orally available MDM2 antagonist with Ki of 0.88 nM. This compound is a diastereomer of MI-773 (CAS: 1303607-07-9). Phase 1.
|
-
Nat Genet, 2025, 57(1):140-153
-
Pharmaceutics, 2023, 15(4)1274
-
bioRxiv, 2023, 10.1101/2023.03.10.531074
|
|
| S2678 |
NSC 207895
|
NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
|
-
PLoS One, 2024, 19(1):e0295629
-
Front Oncol, 2021, 11:582511
-
Genes Dev, 2020, 34(7-8):526-543
|
|
| S7875 |
NVP-CGM097
|
NVP-CGM097 is a highly potent and selective MDM2 inhibitor with Ki value of 1.3 nM for hMDM2 in TR-FRET assay. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway.
|
-
Haematologica, 2022, 10.3324/haematol.2022.280879
-
Cell Death Dis, 2021, 12(1):98
-
Eur J Cancer, 2020, 126:93-103
|
|
| S8606 |
Siremadlin (HDM201)
|
Siremadlin (HDM201) is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction, with an affinity constant for MDM2 in the picomolar range and a selectivity ratio greater than 10000-fold vs MDM4.
|
-
J Exp Clin Cancer Res, 2023, 42(1):9
-
BMC Cancer, 2023, 23(1):47
-
Cell Genom, 2023, 3(7):100321
|
|